基本情報
- 所属
- 日本獣医生命科学大学 獣医学部獣医学科(獣医内科学教室第二) 教授日本臨床獣医学フォーラム 学術顧問
- 学位
- 獣医学博士(日本獣医畜産大学)(BLANK)
- J-GLOBAL ID
- 200901046496925929
- researchmap会員ID
- 1000303666
- 外部リンク
研究キーワード
4研究分野
1学歴
2-
- 1989年
-
- 1989年
委員歴
16-
2008年4月 - 現在
-
2008年4月 - 現在
-
2008年4月 - 現在
-
2008年4月 - 現在
-
2001年2月 - 現在
論文
84-
International Journal of Molecular Sciences 25(11) 2024年6月An angiotensin receptor/neprilysin inhibitor (ARNI), a heart failure treatment, is a combination drug made up of sacubitril, a neprilysin inhibitor, and valsartan, a vascular receptor blocker. No human or veterinary studies regarding the effect of ARNI on renal haemodynamics in the absence of cardiac or renal issues exist. Therefore, we investigated the effect of ARNI on renal haemodynamics in five healthy dogs. ARNI was administered to all five dogs at an oral dose of 20 mg/kg twice daily for 4 weeks. Renal haemodynamics were assessed on the day before ARNI administration (BL), on Day 7, and on Day 28. The glomerular filtration rate (GFR) significantly increased on Day 28 compared to BL and Day 7, whereas renal plasma flow increased on Day 7 and Day 28 compared to BL. Systolic blood pressure significantly decreased between BL and Day 28. Plasma atrial natriuretic peptide (ANP) concentrations increased on Day 7 compared to BL. Additionally, ANP concentrations increased on Day 28 in three of the five dogs. Different ANP concentrations were observed in the remaining two dogs. Both urine output volume and heart rate remained relatively stable and did not exhibit significant change. In conclusion, ARNI may enhance renal haemodynamics in healthy dogs. ARNI could be a valuable drug for treating both heart and kidney disease in dogs.
-
Journal of Small Animal Practice 2023年6月22日
-
Open Veterinary Journal 13(5) 604-604 2023年Background: Plasma N-terminal pro-atrial natriuretic peptide (NT-proANP) and plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) concentrations may be affected by the hydration status.Aim: This study aimed to evaluate the effect of dehydration on plasma NT-proANP and NT-proBNP concentrations in healthy dogs. Methods: This prospective study included five clinically healthy dogs. Furosemide was administered intravenously at 2–4 mg/kg every 1–2 h until completion of the dehydration model. The dehydration model was considered complete when weight loss was ≥5% and findings of dehydration on physical examination were observed. Plasma NT-proANP and NT-proBNP concentrations were compared at three time points: before the dehydration model was created (point 1), at the completion of the dehydration model (point 2), and when dehydration was judged to have improved (point 3). Association between plasma NT-proANP and NT-proBNP concentrations, and each clinical variable (physical examination, blood pressure, blood chemistry, blood gases, and echocardiography) was assessed using linear regression analysis. Results: Plasma NT-proANP concentration decreased significantly from point 2 to point 1 (p < 0.05), whereas plasma NT-proBNP concentration showed a decreasing trend but did not differ significantly between points 1 and 2. Plasma NT-proANP concentration correlated significantly with body weight (R2 = 0.178) and plasma NT-proBNP concentration (R2 = 0.284) (p < 0.05, respectively), and plasma NT-proBNP concentration correlated significantly with electrolytes (sodium, R2 = 0.439; potassium, R2 = 0.444; chloride, R2 = 0.419), and echocardiographic parameters (diastolic left ventricular internal diameter [LVIDd], R2 = 0.519; weight-standardised LVIDd, R2 = 0.535) (p < 0.01, respectively). Conclusion: The plasma NT-proANP concentrations decreased with dehydration. However, the plasma NT-proBNP concentration did not change with mild dehydration and reflected left ventricular morphology.
-
Veterinary record open 9(1) e28 2022年12月BACKGROUND: Ivabradine is used to treat tachycardia; unlike atenolol, it does not affect blood pressure or myocardial contractility. This study compared the impact of ivabradine and atenolol on heart rate (HR) and HR variability (HRV) during a 24 h period, feeding and sleeping times, via a Holter electrocardiogram in healthy cats. We hypothesised that ivabradine and atenolol would lower the HRs equally well, even at times of excitement and rest, such as during feeding and sleep; that ivabradine, unlike atenolol, would have an effect on HRV. METHODS: Five clinically healthy cats were used in the prospective blinded crossover study receiving 3 days of ivabradine (0.30 mg/kg per os twice daily) followed by atenolol (6.25 mg/cat per os twice daily, range 1.3-2.0 mg/kg) or receiving atenolol followed by ivabradine. A placebo period was initiated before the start of the crossover test, data obtained during that period were used as a baseline (BL). Evaluation parameters included HR and HRV, for the whole 24 h period and for feeding and sleeping times, comparing the effect of ivabradine and atenolol with BL. RESULTS: The HR for the whole 24 h, feeding and sleeping times, were significantly lower with ivabradine and atenolol, compared to BL (p < 0.05). The HRV for the whole 24 h and sleeping time were significantly higher after ivabradine compared with BL and after atenolol. CONCLUSIONS: In healthy cats, ivabradine and atenolol significantly reduced the HR regardless of excitement and rest; their effects were comparable. Ivabradine significantly increased HRV in comparison to BL whereas atenolol did not.
-
Veterinary World 2072-2083 2022年8月27日Background and Aim: Electrocardiography (ECG) is an adjunct for cardiac enlargement diagnosis. However, its efficacy in assessing left cardiac remodeling (left atrial and left ventricular enlargement) in dogs with myxomatous mitral valve disease (MMVD) remains unclear. This study aimed to evaluate the association between ECG parameters and left cardiac remodeling and to investigate whether the rate of change in ECG waveforms in the same individual reflected left cardiac remodeling in dogs with MMVD.Materials and Methods: This retrospective study included 20 healthy dogs and 140 dogs with MMVD. Data on clinical variables were obtained through physical examination, thoracic radiography, and echocardiography. The ECG parameters were the P-wave duration, PR interval, QRS complex duration, P-wave amplitude, R-wave amplitude, and mean electrical axis. Dogs with examination data that could be obtained multiple times during the study period were classified into the non-progressive and progressive groups.Results: Only the P-wave and QRS complex durations were selected as significant variables associated with imaging test parameters (p < 0.05); they had a relatively higher discriminatory ability for the left cardiac remodeling than other ECG parameters. The rates of change in the PR interval and R-wave amplitude were significantly higher in the progressive group than in the non-progressive group.Conclusion: In dogs with MMVD, the P-wave and QRS complex durations were significantly correlated with the left cardiac remodeling indicators. Furthermore, an increased rate of change in the PR interval and R-wave amplitude in the same individual may indicate left cardiac remodeling.
MISC
446-
VETERINARY JOURNAL 197(2) 445-450 2013年8月Plasma N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations increase in dogs with azotemia. However, the correlation between glomerular filtration rate (GFR) and NT-proBNP concentrations in dogs has not been evaluated. The objective of this study was to evaluate the correlation between GFR and plasma NT-proBNP concentrations in dogs with chronic kidney disease (CKD). In this retrospective cross-sectional study, plasma creatinine (Cre) and NT-proBNP concentrations, plasma iohexol clearance (PCio) values and blood pressure were measured in dogs with CKD. Dogs were classified according to PCio values into D group (dogs with decreased PCio values), and N group (dogs with normal PCio values). Dogs were further categorized on the basis of their systolic blood pressure and PCio values into NT-D group (normotensive dogs with decreased PCio values), NT-N group (normotensive dogs with normal PCio values), HT-D group (hypertensive dogs with decreased PCio values) and HT-N group (hypertensive dogs with normal PCio values). Significant correlations were observed between plasma NT-proBNP and Cre concentrations (r = 0.360, P < 0.05) and PCio values (r = 0.470, P < 0.01). Plasma NT-proBNP concentrations were significantly higher in the D group than in the N group (P < 0.001). Plasma NT-proBNP concentrations were significantly higher in the HT-D group than in the other three groups (P <= 0.007). No differences in plasma NT-proBNP concentrations were observed between the NT-D and HT-N groups (P = 0.28). Plasma NT-proBNp concentrations were significantly lower in the NT-N group than in the other three groups (P 0043). Our findings suggest that decreased GFR might be associated with increased plasma NT-proBNP concentrations in dogs, similar to that in humans. In addition, the complication of hypertension in CKD might be associated with further increases in plasma NT-proBNP concentrations. In conclusion, the effects of GFR and blood pressure on the plasma NT-proBNP concentration were small, but it could be necessary to consider the effects when this marker is used to evaluate canine cardiac disease. (C) 2013 Elsevier Ltd. All rights reserved.
-
ペット栄養学会誌 16 Suppl_38-Suppl_39 2013年本研究の目的は、慢性腎臓病(CKD)における尿毒素である血漿インドキシル硫酸(IS)濃度の抑制に対する腎臓病用療法の有効性を確認することだった。CKDと診断された犬28頭および猫12頭を対象とした。腎臓病用療法食を摂取している患者では、有意に血漿インドキシル硫酸濃度が低かった。したがって、腎臓病用療法食は血漿インドキシル硫酸を抑制し、このことがCKDの進行抑制につながる可能性を示唆している。
-
日本臨床獣医学フォーラム年次大会プロシーディング 14th(Vol.2) 153-154 2012年9月28日
-
日本臨床獣医学フォーラム年次大会プロシーディング 14th(Vol.1) 328-329 2012年9月28日
-
獣医麻酔外科学雑誌 43(Supplement 1) 243 2012年6月1日
-
日本獣医師会雑誌 = Journal of the Japan Veterinary Medical Association 65(2) 142-146 2012年2月20日各種検査所見に基づき,6歳,避妊済み雌のアメリカン・ショートヘアを拘束型心筋症と診断した。ベナゼブリル(0.5mg/kg)及びスピロノラクトン(2mg/kg)に加え,ピモベンダン(0.25mg/kg)による治療を開始した(いずれも1日2回)。第7病日に食欲及び運動耐性は改善し,胸水が消失した。しかし,第9病日にピモベンダンの投与のみを中止したところ,第14病日にふたたび胸水の貯留が確認された。その後,ピモベンダンの投与を再開し797日間の経過時点で,左房サイズの縮小及び拡張期左室内径の増大が認められ,また投与再開後うっ血症状は再発しなかった。以上のことから,ピモベンダンは拡張障害を特徴とする猫に対する心不全療法の一部として有益な効果を発揮する可能性があると考えられた。
-
動物の循環器 = Advances in animal cardiology 44(2) 41-47 2011年12月1日2歳6カ月齢,去勢オスのノルウェージャン・フォレスト・キャットを各種検査に基づいて肥大型心筋症と診断し,エナラプリルの投与を開始した。第1357病日に左房の高度な拡大が見られたため,ダルテパリン療法を追加した。さらに,第1616病日に左房内に spontaneous echo contrast (SEC) が,そして第2155病日には左心耳内に血栓形成が認められた。本症例は第2229病日に死亡した。SECは拡大した左房内での血液うっ滞により生じ,ヒトでは心房内での血栓形成または血栓塞栓症の危険因子と考えられている。獣医学領域ではSECの臨床的意義に関する記載は極めて限られている。本症例はSECが確認されてから613日間生存したことから,血栓予防療法を含む心不全療法が的確に実施されれば,SECは必ずしも予後不良を示す所見ではないと考えられた。
-
日本臨床獣医学フォーラム年次大会プロシーディング 13th(Vol.1) 383-385 2011年9月16日
書籍等出版物
15講演・口頭発表等
14共同研究・競争的資金等の研究課題
4-
日本学術振興会 科学研究費助成事業 1994年 - 1994年
-
日本学術振興会 科学研究費助成事業 1993年 - 1993年